Novo Nordisk Pill Approval Trade Call

28 days ago

Speaker 1

"All right. Let's start with Novo Nordisk. Right. Their shares have been up as much as 8%. So the big thing, yes, it won the approval to sell that pill version of its we go we shot in the U.S. They expect to launch in early January, about $140, $149 a month. That's what it cost for that, starting to get a dose. But the company really needed the boost. I mean, the stock's nearly halved in value since the start of the year. Should I do this? Absolutely. Why not? I'm a little worried. I'm still worried about it."

The speaker highlights Novo Nordisk's recent approval to market its pill version, noting an anticipated product launch in early January as a potential catalyst, despite recent stock underperformance. The call is to take a position, though tempered by some caution.

Related Stocks